ZA200810381B - Antagonistic anti-human CD40 monoclonal antibody - Google Patents
Antagonistic anti-human CD40 monoclonal antibodyInfo
- Publication number
- ZA200810381B ZA200810381B ZA200810381A ZA200810381A ZA200810381B ZA 200810381 B ZA200810381 B ZA 200810381B ZA 200810381 A ZA200810381 A ZA 200810381A ZA 200810381 A ZA200810381 A ZA 200810381A ZA 200810381 B ZA200810381 B ZA 200810381B
- Authority
- ZA
- South Africa
- Prior art keywords
- human
- monoclonal antibody
- antagonistic anti
- antagonistic
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076028A EP1854810A1 (en) | 2006-05-09 | 2006-05-09 | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200810381B true ZA200810381B (en) | 2010-03-31 |
Family
ID=37635851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200810381A ZA200810381B (en) | 2006-05-09 | 2007-05-09 | Antagonistic anti-human CD40 monoclonal antibody |
| ZA2009/09185A ZA200909185B (en) | 2006-05-09 | 2009-12-23 | Antagonistic anti-human cd40 monoclonal antibody |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2009/09185A ZA200909185B (en) | 2006-05-09 | 2009-12-23 | Antagonistic anti-human cd40 monoclonal antibody |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8669352B2 (es) |
| EP (2) | EP1854810A1 (es) |
| JP (1) | JP5179474B2 (es) |
| KR (1) | KR101506348B1 (es) |
| CN (1) | CN101490086B (es) |
| AR (1) | AR060998A1 (es) |
| AU (1) | AU2007249031B9 (es) |
| BR (1) | BRPI0711355A2 (es) |
| CA (1) | CA2651565A1 (es) |
| CL (1) | CL2007001335A1 (es) |
| DK (1) | DK2019840T3 (es) |
| ES (1) | ES2406163T3 (es) |
| HK (1) | HK1131627A1 (es) |
| IL (1) | IL195196A (es) |
| MX (1) | MX2008014304A (es) |
| NO (1) | NO20085104L (es) |
| NZ (1) | NZ572756A (es) |
| RU (1) | RU2491295C2 (es) |
| TW (1) | TWI455947B (es) |
| WO (1) | WO2007129895A2 (es) |
| ZA (2) | ZA200810381B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2523640T3 (es) | 2006-06-21 | 2014-11-28 | Musc Foundation For Research Development | Direccionamiento del factor H del complemento para el tratamiento de enfermedades |
| ME01699B (me) | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Metode za stimulaciju regeneracije jetre |
| NZ597809A (en) | 2009-08-06 | 2014-05-30 | Genentech Inc | Method to improve virus removal in protein purification |
| MX2012005151A (es) | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| EP3178851B1 (en) * | 2010-03-31 | 2020-04-29 | Boehringer Ingelheim International GmbH | Anti-cd40 antibodies |
| MX2012013233A (es) | 2010-05-14 | 2013-05-20 | Univ Colorado Regents | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. |
| KR20130036276A (ko) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 보체 결합 3의 C3d 조각에 대한 항체들 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| HUE044591T2 (hu) | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
| DK2699601T3 (en) | 2011-04-21 | 2018-04-23 | Bristol Myers Squibb Co | ANTIBODY POLYPEPTIDES ANTAGONIZING CD40 |
| BR112014009069A2 (pt) | 2011-10-13 | 2020-10-27 | Bristol-Myers Squibb Company | polipeptídeos de anticorpo que antagonizam cd40l |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| WO2014200349A1 (en) | 2013-06-13 | 2014-12-18 | Fast Forward Pharmaceutical B.V. | Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| KR102500401B1 (ko) * | 2014-08-07 | 2023-02-15 | 다이이찌 산쿄 가부시키가이샤 | 항 Orai1 항체 |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| SI3303395T1 (sl) | 2015-05-29 | 2020-03-31 | Abbvie Inc. | Protitelesa proti CD40 in njihove uporabe |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| BR112018006360A2 (pt) | 2015-09-30 | 2018-10-09 | Janssen Biotech Inc | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| JP2020511959A (ja) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | ヒト化抗ｃｄ４０抗体 |
| MX2019014375A (es) | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
| CN111263771A (zh) | 2017-11-03 | 2020-06-09 | 诺华股份有限公司 | 用于治疗干燥综合征的抗cd40抗体 |
| CN112119092A (zh) * | 2018-02-12 | 2020-12-22 | 无糖尿病公司 | 改进的拮抗性抗人cd40单克隆抗体 |
| MX2020010722A (es) | 2018-04-13 | 2020-11-06 | Novartis Ag | Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. |
| EP3781203A4 (en) | 2018-04-20 | 2022-04-13 | Lyvgen Biopharma Co., Ltd. | ANTI-CD40 ANTIBODIES AND USES THEREOF |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| EP3856790A4 (en) | 2018-09-28 | 2022-09-28 | Lyvgen Biopharma Holdings Limited | ANTI-CD40 BINDING MOLECULES WITH MODIFIED CF DOMAINS AND THEIR THERAPEUTIC USES |
| US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| CA3121291A1 (en) | 2018-11-30 | 2020-06-04 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
| WO2020108611A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
| US20220098315A1 (en) | 2019-01-11 | 2022-03-31 | Novartis Ag | Anti-cd40 antibodies for use in treatment of hidradenitis |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP3966240A1 (en) | 2019-05-08 | 2022-03-16 | Novartis AG | Anti-cd40 antibodies for use in treatment of t1dm and insulitis |
| CA3148890A1 (en) | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
| CN117500816A (zh) | 2021-08-26 | 2024-02-02 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| ATE258595T1 (de) | 1992-07-09 | 2004-02-15 | Chiron Corp | Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle |
| JP4219985B2 (ja) | 1996-07-23 | 2009-02-04 | タノックス ファーマ ベスローテン フェンノートシャップ | 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導 |
| JP2002512624A (ja) * | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
-
2006
- 2006-05-09 EP EP06076028A patent/EP1854810A1/en not_active Withdrawn
-
2007
- 2007-05-09 ES ES07747426T patent/ES2406163T3/es active Active
- 2007-05-09 US US11/801,344 patent/US8669352B2/en active Active
- 2007-05-09 CN CN200780025878.9A patent/CN101490086B/zh active Active
- 2007-05-09 MX MX2008014304A patent/MX2008014304A/es active IP Right Grant
- 2007-05-09 EP EP07747426A patent/EP2019840B1/en active Active
- 2007-05-09 AU AU2007249031A patent/AU2007249031B9/en active Active
- 2007-05-09 ZA ZA200810381A patent/ZA200810381B/xx unknown
- 2007-05-09 KR KR1020087030080A patent/KR101506348B1/ko active IP Right Grant
- 2007-05-09 DK DK07747426.0T patent/DK2019840T3/da active
- 2007-05-09 BR BRPI0711355-2A patent/BRPI0711355A2/pt not_active IP Right Cessation
- 2007-05-09 WO PCT/NL2007/050202 patent/WO2007129895A2/en active Application Filing
- 2007-05-09 NZ NZ572756A patent/NZ572756A/xx not_active IP Right Cessation
- 2007-05-09 JP JP2009509467A patent/JP5179474B2/ja active Active
- 2007-05-09 CL CL2007001335A patent/CL2007001335A1/es unknown
- 2007-05-09 AR ARP070102017A patent/AR060998A1/es not_active Application Discontinuation
- 2007-05-09 TW TW096116566A patent/TWI455947B/zh not_active IP Right Cessation
- 2007-05-09 CA CA002651565A patent/CA2651565A1/en not_active Abandoned
- 2007-05-09 RU RU2008148303/10A patent/RU2491295C2/ru not_active IP Right Cessation
-
2008
- 2008-11-10 IL IL195196A patent/IL195196A/en active IP Right Grant
- 2008-12-09 NO NO20085104A patent/NO20085104L/no not_active Application Discontinuation
-
2009
- 2009-11-30 HK HK09111185.3A patent/HK1131627A1/xx not_active IP Right Cessation
- 2009-12-23 ZA ZA2009/09185A patent/ZA200909185B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200909185B (en) | Antagonistic anti-human cd40 monoclonal antibody | |
| IL239947A0 (en) | Monoclonal antibodies against 21-il of human origin | |
| HRP20181616T1 (hr) | Potpuno ljudska anti-vap-1 monoklonska antitijela | |
| IL216381A0 (en) | Antagonistic human light-specific human monoclonal antibodies | |
| SG10201404801YA (en) | Monoclonal antibody | |
| ZA200809065B (en) | Humanized c-Kit antibody | |
| IL204835A0 (en) | Humanized antibody | |
| IL193871A0 (en) | Humanized anti-cd20 monoclonal antibody | |
| HK1122579A1 (en) | Uses of anti-cd40 antibodies | |
| IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
| EP1718749A4 (en) | ANTI-AF-20 HUMANIZED MONOCLONAL ANTIBODY | |
| EP2230250A4 (en) | ANTI-HIV MONOCLONAL ANTIBODY | |
| ZA201004770B (en) | Improved humanized anti-human x9-integrin antibody | |
| EP1712564A4 (en) | MONOCLONAL ANTIBODY ANTI-NC1 | |
| ZA200901165B (en) | Antagonistic human light-specific human monoclonal antibodies | |
| GB0415644D0 (en) | Monoclonal antibody | |
| GB0706963D0 (en) | Humanized antibody | |
| GB0706965D0 (en) | Humanized antibody | |
| GB0706964D0 (en) | Humanized antibody |